Loading resource…

Mayo Clinic
This article, published in Mayo Clinic Proceedings, provides a concise review of Glucagon-Like Peptide-1 (GLP1) and Glucose-dependent Insulinotropic Polypeptide (GIP) receptor agonists. It details their effects on the gastrointestinal tract, including common side effects like nausea, vomiting, diarrhea, and constipation, and offers management strategies for primary care physicians. The review also addresses the implications of these medications for endoscopic procedures, such as esophagogastroduodenoscopy and colonoscopy, and highlights the importance of considering underlying conditions when patients experience gastrointestinal symptoms.
Sign in to open
Answers use this document only.
Your first question is free.
Resources from the same specialty and type. Curated links will replace these when added.
Documents that extend or complement this resource.

NaCl 3% BOLUS THERAPY AS EMERGENCY TREATMENT FOR SEVERE HYPONATREMIA: COMPARISON OF 100 ML VERSUS 250 ML
Same clinical topic · Internal Medicine

NACL 3% BOLUS THERAPY AS EMERGENCY TREATMENT FOR SEVERE HYPONATREMIA: COMPARISON OF 100 ML VS 250 ML
Same clinical topic · Internal Medicine

CLINICAL OUTCOMES OF INTENSIVE INPATIENT BLOOD PRESSURE MANAGEMENT IN HOSPITALIZED OLDER ADULTS
Same clinical topic · Internal Medicine

ALBUMIN ADMINISTRATION IN INTERNAL MEDICINE: A JOURNEY BETWEEN EFFECTIVENESS AND FUTILITY
Same clinical topic · Internal Medicine

HIV CASE PRESENTATION
Same clinical topic · Internal Medicine

TUBERCULOSIS
Same clinical topic · Internal Medicine

Chamberlain's Symptoms and Signs in Clinical Medicine
Same clinical topic · Internal Medicine

Fever (acute onset)
Same clinical topic · Internal Medicine
2026 Acute Ischemic Stroke Guideline
Same specialty · Internal Medicine